TNFRSF18 anticorps

N° du produit ABIN2664611

Détail du produit anti-TNFRSF18 anticorps

Antigène: TNFRSF18 (Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TNFRSF18 est non-conjugé

Application: Immunofluorescence (IF), Intracellular Flow Cytometry (ICFC)

Purification: The antibody was purified by affinity chromatography.

Clone: 621

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur TNFRSF18

Antigène: TNFRSF18 (Tumor Necrosis Factor Receptor Superfamily, Member 18 (TNFRSF18))

Autre désignation: CD357 (TNFRSF18 Produits)

Synonymes: anticorps GITR, anticorps TNFRSF18, anticorps AITR, anticorps Gitr, anticorps CD357, anticorps GITR-D, anticorps TNF receptor superfamily member 18, anticorps tumor necrosis factor receptor superfamily, member 18, anticorps TNFRSF18, anticorps Tnfrsf18

Sujet: GITR (glucocorticoid-induced TNF receptor family-regulated gene) is a 25 kD TNF receptor superfamily member (also known as AITR and TNFRSF18). GITR is expressed on activated lymphocytes and is upregulated by T cell receptor engagement. The cytoplasmic domain of GITR is homologous to CD40, 4-1BB and CD27 and has been shown to interact with TRAF 1-3, but not TRAF 5 or 6. GITR signaling has been shown to regulate T cell proliferation and TCR-mediated apoptosis, and to break immunological self-tolerance. GITR binds GITRL and is involved in the development of regulatory T cells and to regulate the activity of Th1 subsets.

Pathways: Cancer Immune Checkpoints